Friday, October 07, 2022

Australian Vaccinologist Opens Up mRNA Vaccine Safety Record in Systematic Literature & Date Review

What’s the real track record of the mRNA-based vaccines developed at a historic rate during the Operation Warp Speed initiative set up by previous President Donald Trump during the first year of the pandemic?

Significant claims were made with a near-selling-like fervor emanating from key federal government agencies in the United States and most other developed nations. The mainstream media overwhelmingly touts only the positive attributes of these products, which are countermeasures to a national declared emergency, America.

As challenges were introduced, from vaccine durability issues to the ongoing mutations---predicted by plenty of scientists who understand RNA viruses such as influenza or HIV/AIDS--the media seemingly presented ready-made talking points that positioned the products overwhelmingly positive. Afterall, billions of taxpayer funds were allocated into not only the early research, clinical development, and manufacturing of the vaccines, but also the heretofore not seen federally sponsored vaccination campaign which served as a marketing support for the primary companies of both Pfizer and Moderna.

Certainly, the products have helped soften the deadly, sharp edge of the COVID-19 pandemic, but what were the cost externalities as measured in human safety, loss productivity, and other costs to society with centralized government overreach of medical activity? Was the safety record claimed what manifested in reality? While the whole world now knows the mRNA vaccines, just like the flu vaccines, couldn’t control the pathogen’s spread in totality (however, there are cases where the vaccine has served to help control the pandemic), how effective are the vaccine products in the real world at controlling the pandemic?

How about staving off more serious disease and death in high-risk populations—the groups that most benefit from such products? An Australian scientist that leads a national and international reference laboratory for respiratory bacterial pathogens involving the identification, serotyping, genotyping, sequencing, and antimicrobial sensitivity testing for both veterinary and pharmaceutical clients, along with a colleague released a sharp critique of the COVID-19 vaccines.

Dr. Conny Turni and colleague Astrid Lefringhausen explore the above topics in “COVID-19 Vaccines—An Australian Review” published in the Journal of Clinical & Experimental Immunology.

No Lightweight Prose

With expertise in vaccines and topics such as antibiotic sensitivity for determining optimal sample sites for collecting pathogens as well as understanding the connections of different pathogens with disease, the development of animal infection models, and classification of bacteria and epidemiology of pathogens, Dr. Turni is no lightweight.

Profound Questions

Why have hundreds of millions worldwide needed to be vaccinated as many as four times within a twelve-month period? What are the effects of this ongoing countermeasure-driven medical endeavor on the human body? The clinical trial basis of the authorization was based only on a primary series of mRNA-based vaccines (two doses). Taking an Australian perspective, which TrialSite has followed, this demonstrates that double the number of persons died Down Under in the first three months of 2022 than all of 2020 and 2021 despite an already very high vaccination rate by the start of the year.

What were the promises and predictions from Australian authorities versus the actual facts on the ground? How about the safety and efficacy? Is there a substantial delta between what was promoted versus actuals? Just how safe, or unsafe are the countermeasures? What are the long-term side effects and how do these impact risk-benefit analyses?

Conducting a systematic literature and government data review, the authors establish the situation that merits investigation—the intensive push by the government for nearly everyone (including children as young as five and pregnant women) to get vaccinated. Yet, clinical research in all reality was ongoing. With a fourth booster dose administered in the elderly and other at-risk persons in just over a year from the first primary series, the long-term externalities as measured in human health cannot be known.

Crisis-driven Innovation

Vaccines often take many years to develop due to the difficulty associated with the development of this class of medical intervention—typically, a biological preparation that offers the human host active acquired immunity to a particular infectious pathogen. The vaccine usually contains an agent (like a weakened virus) that stimulates the human body’s immune system to not only recognize but also destroy the specific threat.

Vaccines are powerful medicinal interventions, and along with public health infrastructure breakthroughs over a century ago, helped transform developed economies. Some vaccines all but prevent the disease; they have served to control what were once horrific diseases such as polio. Others are used more as a therapeutic agent prophylactically to reduce the probability of the health threat such as with the influenza vaccine. While during the development and the authorization the COVID-19 vaccines were promoted like the former, in reality they perform like the latter scenario.

mRNA, developed over the last couple decades, introduced a new genetic way of inducing the human immune system’s ability to fight and overtake viruses. The onset of COVID-19 was the event fully exploited by the pharmaceutical industry and government research agencies to leverage public resources and assets to rapidly advance this promising technology. With COVID-19 came the intervention needed to achieve a faster, more economical, and adept way to produce vaccines. Done under national and global emergency, the countermeasures had to be safe and effective.

A Tenuous Foundation

First, in the “Initial Information” section of this literature review, Dr. Turni and Ms. Lefringhausen point out that the producers of the vaccines, government health agencies, and medical societies all declared that the “mRNA vaccines were supposed to remain at the injection site and be taken up by the lymphatic system.” This, and other basic premises represented a vital covenant with the public.

Yet according to the authors, “this assumption proved to be wrong.” They point to an autopsy of a person that unfortunately died as a result of the mRNA vaccination: “It was found that the vaccine disperses rapidly from the injection site and can be found in nearly all parts of the body.”

TrialSite has tracked numerous studies, mostly case series based on one death that evidence temporary wide distribution of the spike protein throughout the body for some short period of time.

The Australian literature review authors point out that although positioned to the contrary, the vaccine payload could cross both the blood-brain barrier and the blood-placenta barrier which is referenced in a European Medicines Agency assessment report targeting Moderna’s vaccine. They note, “mRNA could be detected in the brain following intramuscular administration at about 2% of the level found in plasma.” See the report on page 47: assessment-report/spikevax-previously-covid-19-vaccine [1]moderna-epar-public-assessment-report_en.pdf (the EMA has taken the report down).

The authors also point to 2021, when Japanese researchers found “a disproportionately high mortality due to cerebral venous sinus thrombosis and intracranial hemorrhaging,” but this causal link couldn’t be proven. Yet authorities didn’t bother to do autopsies. Again, TrialSite has reported on many dozens of examples of post-vaccine injury studies mostly in the form of summaries of case series.

What about the claim “that the mRNA will degrade quickly?” While mRNA is supposed to break down within a few minutes to hours, writes the authors, the COVID-19 vaccines is “nucleoside-modified to reduce potential innate immune recognition, and it has been shown that production of the spike protein in some vaccines is kept up for an extraordinary long time.”

The Australians point to studies such as Röltgen et al, for examples showing that the mRNA vaccine may persist in the human body for up to 60 days. In fact, the 60 days was the endpoint so the duration could be longer. The authors declare, “It is thus unknown and impossible to define how much of the spike protein is actually produced in the vaccinated.” How about how much antigen is associated with each dose injection? Dr. Turni and Ms. Lefringhausen point out that:

“For a ‘so-called’ vaccine that is using the human body as the production facility, there is no possible quantification of antigen. This is highly variable and dependent on the amount and stability of nanoparticles in the injection, age, and fitness of the vaccinee, their immune status, and the injection technique—if a blood vessel is directly injected, the nanoparticles will travel in minutes to all major organs including the brain. It is therefore impossible to assess how much spike protein any individual vaccinee produces following an inoculation.”


COVID Mandates Are Being Lifted but Still Continue—End the "National Emergency"

In the last two years, many states in America experienced highly coercive and authoritarian enforcement of the COVID “vaccine,” “shot” or “jab,” particularly among the federal, military, corporate, medical and academic sectors.

It would be an understatement to suggest that many Americans thought their community had transformed into a police state. But there was pushback by those who championed personal liberty—to assert one’s right as a sovereign human being, as a member of “we, the people,” and not as a property of the state.

And here is an fascinating statistic: while 60 to 70 percent of people in Canada and many European nations have received an additional COVID shot following the two-dose protocol, only 33 percent of the U.S. population have received a booster dose as of September 20.

Now, a number of large corporations have dropped their mandate.

The Goldman Sachs Group, Inc. has reportedly lifted all COVID-related requirements. The global financial institution will no longer require its employees to be jabbed or tested and wear face masks to enter most offices. However, unjabbed workers in New York City (NYC) will still need an approved religious or medical exemption to enter office spaces.

Moreover, JPMorgan Chase & Co. also changed its policy in March, stating they will hire unjabbed individuals again.

According to an announcement on Cisco Systems, Inc.’s website in June, the worldwide leader in IT and networking has ceased to require inoculated employees for “office entry, travel, event attendance, or visiting customers, partners, and other third parties.”

The reasons behind these decisions are arguably multifactorial, perhaps in response to an updated “guidance” from federal health officials or a potential staff shortage.

Jeff Levin-Scherz, a population health leader & Assistant Professor at Harvard Chan School of Public Health, reasons these companies “decided that the rationale for [mandates] had become weak enough that they don’t want to continue.”

Erin Grau is the co-founder & COO of Charter, a media company focused on transforming every workplace to “catalyze a new era of dynamic organizations where all workers thrive.” According to Axios, she states there is an effort by executives to reduce any barriers to entry for new hires. Furthermore, the COVID-related requirements are reportedly expensive and time-consuming for employers. Frankly, it’s one big unnecessary hassle.

And to this end, here’s a shoutout to the folks in the Big Apple. In late September, it was reported that private businesses in NYC could stop demanding that their employees be jabbed, starting in early November. Instead, the private sector companies will be permitted to establish their own “vaccine” policies. However, this new rule doesn’t apply to city workers, who will still need to show evidence of inoculation to contribute to the economy.

Some clinics and airlines have (sort of) followed suit
As early as mid-December 2021, some of the largest U.S. hospital systems dropped employee COVID requirements. According to The Wall Street Journal, Tenet Healthcare and Cleveland Clinic were among the companies dropping the mandates.

Such a policy change occurred as several hospitals dealt with ongoing labor shortages and increased labor costs. For example, a Mercer Healthcare industry leader told CBS12 News, “Even a loss of a few people in healthcare today is much more problematic than it’s ever been. The industry is having a heck of a time dealing with turnover.” Indeed, for some, the COVID shots mandate could be “the straw that breaks the camel’s back.”

It’s a numbers game. The more people refuse to comply with such invasive rules, the less likely it’s possible for any federal-based or private-based company to enforce these coercive policies. Such institutions can keep terminating employment or push workers aside with unpaid leave—but practically speaking, for how many and for how long?




No comments: